Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Recombinant growth hormone treatment for AIDS/HIV-associated wasting and lipodystrophy. Lansdale: HAYES, Inc.. Directory Publication. 2012 Authors' conclusions Recombinant human growth hormone (rhGH) is used in the treatment of AIDS-associated wasting and lipodystrophy; tesamorelin, an analog of growth hormone–releasing factor (GHRF), is used for treatment of AIDS-associated lipodystrophy. The goal of these treatments is to increase lean body mass in patients with human immunodeficiency virus (HIV)-associated wasting and to reduce AIDSrelated abnormal morphologic and metabolic changes in HIV patients with lipodystrophy. Indexing Status Subject indexing assigned by CRD MeSH HIV-Associated Lipodystrophy Syndrome Growth Hormones Language Published English Country of organisation United States English summary An English language summary is available. Address for correspondence HAYES, Inc., 157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218 Email: hayesinfo@hayesinc.com AccessionNumber 32013000154 Date abstract record published 20/03/2013 |